Complement Inactivating Agents

Name
Complement Inactivating Agents
Accession Number
DBCAT001769
Description

Compounds that negatively regulate the cascade process of COMPLEMENT ACTIVATION. Uncontrolled complement activation and resulting cell lysis is potentially dangerous for the host.

Drugs
DrugDrug Description
EculizumabA recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
IcatibantA bradykinin B2 receptor antagonist used to treat acute episodes of swelling and inflammation associated with hereditary angioedema (HAE).
Human C1-esterase inhibitorA C1 inhibitor used to prevent angioedema attacks associated with hereditary angioedema.
NafamostatUsed as an anticoagulant in patients with disseminative blood vessel coagulation, hemorrhagic lesions, and hemorrhagic tendencies. It prevents blood clot formation during extracorporeal circulation in patients undergoing continuous renal replacement...
RavulizumabA monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria.
LanadelumabA plasma kallikrein inhibitor used to treat attacks of hereditary angioedema.
FasitibantFasitibant is under investigation in clinical trial NCT02205814 (Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee).
Drugs & Drug Targets
DrugTargetType
EculizumabComplement C5target
IcatibantB2 bradykinin receptortarget
IcatibantAminopeptidase Ntarget
Human C1-esterase inhibitorComplement C1r subcomponenttarget
Human C1-esterase inhibitorComplement C1s subcomponenttarget
Human C1-esterase inhibitorPlasma kallikreintarget
Human C1-esterase inhibitorCoagulation factor XIItarget
Human C1-esterase inhibitorProthrombintarget
Human C1-esterase inhibitorCoagulation factor XItarget
Human C1-esterase inhibitorTissue-type plasminogen activatortarget
NafamostatIntercellular adhesion molecule 1target
NafamostatTrypsin-1target
NafamostatKallikrein-1target
NafamostatProthrombintarget
NafamostatCoagulation factor Xtarget
NafamostatCoagulation factor XIItarget
NafamostatSolute carrier family 22 member 1transporter
NafamostatSolute carrier family 22 member 2transporter
RavulizumabComplement C5target
LanadelumabPlasma kallikreintarget